Summit Therapeutics Inc.: financial statements

SMMTNASDAQHealthcare · Pharmaceutical Preparations

Price

$9.95

November 20, 2026Market cap $7.7B

What Ploutos Investor adds for Summit Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from FY2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 38% since Nov 4, 2026, when the 10-Q these figures come from was filed ($16.17 then, $9.95 on Nov 20, 2026). The figures date from before that move.10-Q

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

Line202320242025Average a year
Revenue $0$0–
Operating income -$610M-$226M-$1.1B
Net income -$615M-$221M-$1.1B
Earnings per share -$0.99-$0.31-$1.44
Earnings per share, basic -$0.99-$0.31-$1.44

Financial statements

SMMT's revenue, profits and cash flows from FY2016 to 2022, 7 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • FY2019: License And Service $57M, Research Collaboration Agreements $327.0K
ProductFY2019Share FY2019
License And Service$57M99%
Research Collaboration Agreements$327.0K0.6%

From the XBRL of 10 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

In some years the company reports no operating income, so we show pre-tax income.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$21M Leases0.0% Effective tax rate

Leases

Dec 31, 2025

Operating leases

$21M

Finance leases

–

Average discount rate
7.6%
Lease cost for the year
$3.9M

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Operating lease payments by year

Lease liability by year

Leases

SMMT's leases from 2019 to 2022, 4 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Goodwill by segment

Dec 31, 2025

Total goodwill

$2.0M

The company does not state its goodwill by segment, at December 31, 2025. The filing

Goodwill by year

Goodwill by year

SMMT's goodwill from FY2019 to 2022, 5 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

0.0%

-21.0 pts

The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Tax credits

+0.6 pts

Share-based compensation

-12.4 pts

Foreign rate differential · Cayman Islands

-6.3 pts

Change in valuation allowance

-2.7 pts

Smaller lines (2)

-0.2 pts

Effective rate

0.0%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Effective tax rate by year

Effective tax rate by year

The tax rate SMMT paid on its profit, from FY2019 to 2022, 5 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.

The full analysis

What do Summit Therapeutics's filings show?

These are Summit Therapeutics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about SMMT's financials

Didn't find what you were looking for?

Ask us
How much debt does SMMT have?

On December 31, 2025 Summit Therapeutics had total assets of $751M, debt of – and shareholders' equity of $659M.

How much free cash flow does SMMT have?

In fiscal 2025 Summit Therapeutics had cash from operations of -$323M and spent $657.0K on capital expenditure, leaving -$324M of free cash flow.

Where are the figures from?

From Summit Therapeutics Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.